Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent®) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer
- 26 June 2007
- journal article
- research article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 134 (1), 51-57
- https://doi.org/10.1007/s00432-007-0247-4
Abstract
Physiological and molecular findings indicate over-expression of HER proteins and dysregulation of neo-angiogenesis during progression of advanced prostate cancer. The aim of this study was to test a novel rational therapeutic approach by combining docetaxel with an EGFR-targeting agent (cetuximab) and with an anti-angiogenic agent (sunitinib, SUTENT®).Keywords
This publication has 31 references indexed in Scilit:
- Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126British Journal of Cancer, 2006
- Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel–erlotinib and 5-fluoro-5′-deoxyuridineAnti-Cancer Drugs, 2006
- Targeting Platelet-Derived Growth Factor Receptor on Endothelial Cells of Multidrug-Resistant Prostate CancerJNCI Journal of the National Cancer Institute, 2006
- SSeCKS Metastasis-Suppressing Activity in MatLyLu Prostate Cancer Cells Correlates with Vascular Endothelial Growth Factor InhibitionCancer Research, 2006
- Synergistic Antitumor Effects of Combined Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor Receptor-2 Targeted TherapyClinical Cancer Research, 2006
- A Multitargeted, Metronomic, and Maximum-Tolerated Dose “Chemo-Switch” Regimen is Antiangiogenic, Producing Objective Responses and Survival Benefit in a Mouse Model of CancerJournal of Clinical Oncology, 2005
- Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials GroupJournal of Clinical Oncology, 2005
- Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activityThrombosis and Haemostasis, 2005
- The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate CancerJournal of Urology, 2003
- Phase I studies of ZD1839 in patients with common solid tumorsSeminars in Oncology, 2003